Congenital abnormalities and acquired disorders can lead to organ damage and loss. Nowadays, transplantation represents the only effective treatment option. However, there is a marked decrease in the number of organ donors, which is even yearly worsening due to the population aging. The regenerative medicine represents a realistic option that allows to restore and maintain the normal functions of tissues and organs. This article reviews the principles of regenerative medicine and the recent advances with regard to its application to the genitourinary tract.
Recent findings
The field of regenerative medicine involves different areas of technology, such as tissue engineering, stem cells and cloning. Tissue engineering involves the field of cell transplantation, materials science and engineering in order to create functional replacement tissues. Stem cells and cloning permit the extraction of pluripotent, embryonic stem cells offering a potentially limitless source of cells for tissue engineering applications. Most current strategies for tissue engineering depend upon a sample of autologous cells from the patient's diseased organ. Biopsies from patients with extensive end-stage organ failure, however, may not yield enough normal cells. In these situations, stem cells are envisaged as being an alternative source. Stem cells can be derived from discarded human embryos (human embryonic stem cells), from fetal tissue or from adult sources (bone marrow, fat, skin). Therapeutic cloning offers a potentially limitless source of cells for tissue engineering applications.
Regenerative medicine and tissue engineering scientists have increasingly applied the principles of cell transplantation, materials science and bioengineering to construct biological substitutes that will restore and maintain normal function in urological diseased and injured tissues such as kidney, ureter, bladder, urethra and penis.
Conclusions
Regenerative medicine offers several applications in acquired and congenital genitourinary diseases. Tissue engineering, stem cells and, mostly, cloning have been applied in experimental studies with excellent results. Few preliminary human applications have been developed with promising results.
National Institute of Biomedical Imaging and Bioengineering, June 2004.
2.
ChenF., YooJ.J., AtalaA.Acellular collagen matrix as a possible ‘off the shelf’ biomaterial for urethral repair.Urology1999; 54: 407–10.
3.
DahmsS.E., PiechotaH.J., DahiyaR., LueT.F., TanaghoE.A.Composition and biomechanical properties of the bladder acellular matrix graft: comparative analysis in rat, pig, and human.Br J Urol1998; 82: 411–9.
4.
PiechotaH.J., DahmsS.E., NunesL.S., DahiyaR., LueT.F., TanaghoE.A.In vitro functional properties of the rat bladder regenerated by the bladder acellular matrix graft.J Urol1998; 159: 1717–24.
5.
YooJ.J., MengJ., OberpenningF., AtalaA.Bladder agumentation using allogenic bladder submucosa seeded with cells.Urology1998; 51: 221–225.
6.
BergsmaJ.E., RozemaF.R., BosR.R., BoeringG., de BruijnW.C., PenningsA.J.In vivo degradation and biocompatibility study of in vitro pre-degraded as-polymerized polyactide particles.Biomaterials1995; 16: 267–274.
7.
KimB., and MooneyD.J.Development of biocompatible synthetic extracellular matrices for tissue engineering.Trends Biotechnol.1998; 16: 224–230.
8.
HynesR.O.Integrins: versatility, modulation, and signaling in cell adhesion.Cell1992; 69: 11–25.
9.
DeuelT.F.Growth factors. In: Principles of Tissue Engineering 133–149 (Eds LanzerRP) New York: Academic Press; 1997
10.
ParienteJ.L., KimB.S., AtalaA.In vitro biocompatibility assessment of naturally derived and synthetic biomaterials using normal urothelial cells.J Biomed Mater Res2001; 55: 33–39.
11.
ParienteJ.L., KimB.S., AtalaA.In vitro biocompatibility evaluation of naturally derived and synthetic biomaterials using normal human bladder smooth muscle cells.J Urol2002; 167: 1867–71.
SilverF.H., and PinsG.Cell growth on collagen: a review of tissue engineering using scaffolds containing extracellular matrix.J Long Term Eff Med Implants1992; 2: 67–80.
14.
SmidsrodO., and Skjak-BraekG.Alginate as immobilization matrix for cells.Trends biotechnol.8: 71–80.
MikosA.G.Preparation and characterization of poly (L-lactic acid) foams.Polymer1994; 35: 1068–77.
18.
HarrisL.D., KimB.S., MooneyD.J.Open pore biodegradable matrices formed with gas foaming.J Biomed Mater Res1998; 42: 396–402.
19.
HumesH.D., BuffingtonD.A., MacKayS.M., FunkeA.J., WeitzelWF.Replacement of renal function in uremic animals with a tissue engineered kidney.Nat Biothecnol1999; 17: 451–5.
20.
HumesH.D., WeitzelW.F., BartlettR.H., SwanikerF.C., PaganiniEP.Renal cell therapy is associated with dynamic and individualized responses in patients with acute renal failure.Blood Purif2003; 21: 64–71.
21.
YooJ.J., AshKar, AtalaA.Creation of functional kidney structures with excretion of urine-like fluid. In vivo.Pediatrics1996; 98(Suppl.): 605.
22.
DahmsS.E., PiechotaH.J., NunesL., DahiyaR., LueT.F., TanaghoE.A.Free ureteral replacement in rats: regeneration of ureteral wall components in the acellular matrix graft.Urology1997; 50: 818–25.
23.
BaltaciS., OzerG., OzerE., SoygürT., Be altiO., AnafartaK.Failure of ureteral replacement with Goretex tube grafts.Urology1998; 51: 400–3.
24.
OsmanY., ShokeirA., GabrM., El-TabeyN., MohsenT., El-BazM.Canine ureteral replacement with long acellular matrix tube: is it clinically applicable ?J Urol2004; 172: 1151–4.
25.
YooJ.J., SatarN., RetikA.B., AtalaA.Ureteral replacement using biodegradable polymer scaffolds seeded with urothelial and smooth muscle cells.J Urol1995; 153(Suppl): 375A.
26.
MatsunumaH., KagamiH., NaritaY.Constructing a tissue-engineered ureter using a decellularized matrix with cultured uroepithelial cells and bone marrow-derived mononuclear cells.Tissue Eng2006; 12: 509–18.
27.
McDougalW.S.Metabolic complications of urinary intestinal diversion.J Urol1992; 147: 1999–208.
28.
KaeferM., HendrenW.H., BauerS.B.Reservoir calculi: a comparison of reservoirs constructed from stomach and other enteric segments.J Urol1998; 160: 2187–90.
OberpenningF., MengJ., YooJ.J., AtalaA.De novo reconstruction of a functional urinary bladder by tissue engineering.Nat Biotechnol1999; 17: 149–55.
31.
KorossisS., BollandF., InghamE., FisherJ., KearneyJ., SouthgateJ.Review: tissue engineering of the urinary bladder: Considering structure-function relationships and the role of mechanotransduction.Tissue Eng2006; 12: 635–44.
32.
SievertK.D., FandelT., WeferJ.Collagen I: III ratio in canine heterologous bladder acellular matrix grafts.World J Urol2006; 24: 101–9.
KershenR.T., YooJ.J., MorelandR.B., KraneR.J., AtalaA.Reconstruction of human corpus cavernosum smooth muscle in vitro and in vivo.Tissue Eng2002; 8: 515–24.
ThomsonJ.A., Itskovitz-EldorJ., ShapiroS.S.Embryonic stem cell lines derived from human blastocysts.Science1998; 282: 1145–7.
48.
HoffmanD.I., ZellmanG.L., FairC.C.Cryopreserved embryos in the United States and their availability for research.Fertil Steril2003; 79: 1063–9.
49.
CampbellK.H., McWhirJ., RitchieW.A., WilmutI.Sheep cloned by nuclea transfer from a cultured cell line.Nature1996; 380: 64–6.
50.
PolejaevaI.A., ChenS.H., VaughtT.D.Cloned pigs produced by nuclear transfer from adult somatic cells.Nature2000; 407: 86–90.
51.
ColmanA., KindA.Therapeutic cloning: concepts and practicalities.Trends Biothecnol2000; 18: 192–6.
52.
VogelsteinB., AlbertsB., ShineK.Genetics.Please don't call it cloning! Science2002; 295: 1237.
53.
HochedlingerK., JaenischR.Nuclear transplantation, embryonic stem cells and the potential for cell therapy.N Engl J Med2003, 349: 275–86.
54.
LanzaR.P., ChungH.Y., YooJ.J.Generation of histocompatible tissues using nuclear transplantation.Nat Biothecnol2002; 20: 689–96.
55.
HischikawaK., FujitaT.Stem cells and kidney disease.Hypertens Res2006; 29: 745–9.
56.
FekiA., FaltinD.L., LeiT., DubuissonJ.B., JacobS., IrionO.Sphincter incontinence: is regenerative medicine the best alternative to restore urinary or anal sphincter function?Int J Biochem Cell Biol2007; 39: 678–84. Epub 2006 Nov 7.
57.
JackG.S., AlmeidaF.G., ZhangR., AlfonsoZ.C., ZukP.A., RodríguezL.V.Processed lipoaspirate cells for tissue engineering of the lower urinary tract: implications for the treatment of stress urinary incontinence and bladder reconstruction.J Urol2005; 174: 2041–5.
